Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2323 results about "Cellular Cytotoxicity" patented technology

Antibody-dependent cell-mediated cytotoxicity (ADCC) (antibody-dependent cellular cytotoxicity) lysis of target cells coated with antibody by effector cells with cytolytic activity and specific immunoglobulin receptors called Fc receptors, including K cells, macrophages, and granulocytes.

Recombinant human IV-type collagen as well as preparation method and application thereof

The invention belongs to the technical field of optimized coding genes, and discloses a recombinant human IV-type collagen as well as a preparation method and application thereof, and the amino acid sequence of the recombinant human IV-type collagen is shown as SEQ ID No.1. Experiments prove that the collagen provided by the invention has the advantages of higher yield, better cell proliferation promoting performance, no cytotoxicity and high safety, and can be widely applied to the fields of medicines, medical instruments, biological materials, tissue engineering and the like.
Owner:HEBEI NACO BIOTECHNOLOGY CO LTD

Treatment of lung cancer using a combination of an Anti-PD-1 antibody and another Anti-cancer agent

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.
Owner:BRISTOL MYERS SQUIBB CO

Antibacterial oligopeptide with high protease stability as well as preparation method and application of antibacterial oligopeptide

The invention discloses an antibacterial oligopeptide with high protease stability as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The amino acid sequence of the antibacterial short peptide DabDab is LWDabLDabWDaab-NH2, the C end of the antibacterial short peptide DabDab is amidated by adopting-NH2, and the Dab is 2, 4-diaminobutyric acid. Detection on antibacterial activity, hemolytic activity, cytotoxicity and protease stability of the antibacterial oligopeptide DabDab shows that the antibacterial oligopeptide DabDab has high antibacterial activity on several determined gram-negative bacteria and has certain antibacterial activity on several determined gram-positive bacteria. The cell selectivity of the antibacterial oligopeptide DabDab is relatively high, TI is equal to 16.00, and the antibacterial oligopeptide DabDab does not show obvious cytotoxicity under the condition of 128 mu g / mL. The antibacterial oligopeptide DabDab still maintains the original MIC or the MIC is only increased by 2 times after being incubated with pepsase or trypsin for 8 hours, and the antibacterial oligopeptide DabDab has high protease stability.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

An improved process for purification of fusion protein

The present invention relates to purification process of pharmacologically active cytotoxic T lymphocyte-associated 4-immunoglobulin (CTLA4-lg) fusion protein by using three column chromatography steps that provides purified form of the fusion protein, substantially free of misfolded species, charge variants and aggregates. A method for purifying a fusion protein from a protein mixture comprising a fusion protein and high molecular weight (HMW) impurity.
Owner:ACQUIOM AGENCY SERVICES LLC AS COLLATERAL AGENT

Platinum-acridine compounds and methods of treating cancers

Platinum-acridines and analogs thereof as cytotoxic agents for cancer treatment. Also provided methods of using hMATE1 (SLC47A1) as a biomarker to identify tumors that are likely to respond to the agents, and epigenetically sensitizing tumor tissue to anticancer drugs targeting this membrane transporter.
Owner:WAKE FOREST UNIV

Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
Owner:BRISTOL MYERS SQUIBB CO

Fc-epsilon CAR

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK / NK-92 cells.
Owner:IMMUNITYBIO INC

Epidermal growth factor connecting polypeptide and application thereof in endometrial injury repair

The invention belongs to the technical field of biological medicines, and particularly discloses an epidermal growth factor-linker polypeptide-collagen, and the linker polypeptide has an amino acid sequence as shown in SEQ ID No.1. The linker polypeptide capable of connecting the EGF and the collagen is designed and synthesized, the N end of the linker polypeptide simulates an EGF receptor structure and can be combined with the EGF, and the linker polypeptide is connected with the EGF through non-covalent Van der Waals force, so that the structure of the EGF cannot be damaged; the C terminal of the linker polypeptide is rich in lysine residues, and can be covalently crosslinked to collagen through glutamine transaminase to form EGF-linker polypeptide-collagen. The protein solution taking EGF-linker polypeptide-collagen as active ingredients is low in cytotoxicity and high in biological safety, and meanwhile, the action time of the epidermal growth factor can be remarkably prolonged. In addition, a stable repairing microenvironment can be formed on the surface of the endometrium, and the endometrium injury repairing effect is remarkably improved.
Owner:SHOUXI (GUANGZHOU) MEDICAL TECH CO LTD

Conotoxin-derived anticoagulant polypeptide Cb-13 and application thereof

The invention provides conotoxin-derived anticoagulant polypeptide Cb-13 and application thereof, and belongs to the technical field of biological medicine. The invention provides an anticoagulant polypeptide Cb-13. The amino acid sequence of the anticoagulant polypeptide Cb-13 comprises SEQ ID No.1. The invention also provides a coding gene of the anticoagulant polypeptide Cb-13, and provides that the anticoagulant polypeptide Cb-13 does not have hemolytic activity and does not have cytotoxicity when the concentration is 400 [mu] M or below. The anticoagulant polypeptide Cb-13 disclosed by the invention has a prolonging effect on plasma recalcification and coagulation time, has an anticoagulant effect, has small influence on bleeding, and also has an obvious promoting effect on plasmin and uPa. Meanwhile, it is also proved that the anticoagulant polypeptide Cb-13 can inhibit thrombus formation, that is, the anticoagulant polypeptide Cb-13 has in-vivo and in-vitro fibrinolytic effect and anticoagulant effect, has small bleeding risk, and can be used as an antithrombotic or thrombolytic drug.
Owner:ANHUI UNIV +1

Preparation and application of bionic cerium-based polyphenol nano-enzyme for treating rheumatoid arthritis

The invention discloses preparation and application of bionic cerium-based polyphenol nano-enzyme for treating rheumatoid arthritis, and belongs to the field of medical preparations. The method comprises the following steps: respectively complexing cerium ions and tannic acid or epicatechin gallate to prepare cerium-based polyphenol nano-enzyme, and then preparing the cerium-based polyphenol nano-enzyme wrapped by a macrophage membrane. And loading the cerium-based polyphenol nano-enzyme wrapped by the macrophage membrane into the hydrogel to prepare the hyaluronic acid-based hydrogel. The cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are characterized, it is verified that the cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are successfully synthesized, the particle size of CeTA is about 22 nm, the particle size of M-CeTA is increased to 273 nm, the particle size of CeECG is about 95 nm, and the particle size of M-CeECG is increased to 292 nm. In-vitro experiments prove that the M-CeTA and the M-CeECG do not show obvious cytotoxicity when being less than 80 mu g / mL, and have an obvious inhibition effect on expression of cell inflammatory factors on inflammatory cells.
Owner:YANTAI UNIV

New application of PBMC (peripheral blood mononuclear cell)-derived cytotoxic T cell

The present invention relates to: a method for evaluating the efficacy of an anti-cancer drug, a method for screening an anti-cancer drug, a system for evaluating the efficacy of an anti-cancer drug, or a system for screening an anti-cancer drug, using a mixture of peripheral blood mononuclear cells (PBMC) and a cancer organoid. Specifically, the present invention relates to: a method for evaluating the efficacy of an anti-cancer drug, a method for screening an anti-cancer drug, a system for evaluating the efficacy of an anti-cancer drug, or a system for screening an anti-cancer drug, using a mixture of cytotoxic T cells differentiated from PBMC and cancer organoids. According to the method for evaluating the efficacy of an anti-cancer drug, the screening method, the efficacy evaluation system, or the screening system of the present invention, a tumor microenvironment, i.e. The form in which cancer cells are present in a living body, can be very closely reproduced. Furthermore, since PBMCs derived from normal individuals are used and differentiated into cancer patient-specific cytotoxic T cells, the burden of collecting biological samples such as blood and tissue samples from cancer patients can be reduced, and the efficacy of an anti-cancer drug can be evaluated with high accuracy.
Owner:ORGANOIDSCIENCES LTD

Antibody variants and uses thereof

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
Owner:GENMAB BV

Recombinant IV type collagen Pro.C4 as well as preparation method and application thereof

The invention discloses a recombinant IV type collagen Pro.C4. The recombinant IV type collagen Pro.C4 is characterized in that the amino acid sequence of the recombinant IV type collagen Pro.C4 is shown as any one of SEQ ID NO.1-5. The invention also discloses a coding gene, an expression vector, host bacteria and application of the gene. The recombinant human IV-type collagen is designed on the basis of partial sequences in alpha 1 and alpha 2 chains of the human IV-type collagen, prokaryotes are used for expressing protein, an expression system is mature, and the purified recombinant IV-type collagen is free of cytotoxicity through experimental verification, has better cell repairing and tightening effects, and can be used for preparing the recombinant human IV-type collagen. The material can be used as a biological material applied to beauty products and the like.
Owner:广东普言生物科技有限公司

Functional drug-loaded small molecule peptide for promoting ferroptosis of breast cancer cells

The invention discloses a functional drug-loaded small molecule peptide for promoting ferroptosis of breast cancer cells, and belongs to the technical field of establishment and preparation of a small molecule peptide nano-drug carrier system. The functional small molecule peptide responds to subacidity in a tumor microenvironment, can be used as a drug carrier, and has a structural formula as shown in Figure 1. The functional drug-loading small molecule peptide system PS / Pep1 can target blood coagulation plasma protein in tumor blood vessels, and can improve the cytotoxicity to tumor cells and reduce the toxic and side effects to normal cells. The PS / Pep1 is subjected to morphology transformation in a tumor microenvironment, and the PS / Pep1 carries PTX and SF together, so that the residence time of the combined drug in tumor cells is prolonged. Compared with PS / Pep2 of which the morphology cannot be transformed, PS / Pep1 can more effectively inhibit the growth of tumors. More importantly, PS / Pep1 can effectively induce ferroptosis of breast cancer cells.
Owner:WEIFANG MEDICAL UNIV

HER2 positive breast cancer targeting functional drug-loading small molecule peptide

The invention discloses a functional drug-loading small molecule peptide targeting HER2 positive breast cancer, and belongs to the technical field of establishment and preparation of a small molecule peptide nano-drug carrier system. The peptide contains HER2 targeting peptide, responds to alkaline phosphatase in a tumor microenvironment, can be used as a drug carrier, and has a structural formula as shown in Figure 1. The functional drug-loading small molecule peptide can improve the cytotoxicity to tumor cells and reduce the toxic and side effects to normal cells. The DC / Pep1 is subjected to morphology transformation under the induction of ALP in a tumor microenvironment, and the DC / Pep1 carries DOX and CUR together, so that the residence time of the combined drug in HER2 positive tumor cells is prolonged, and tumor cell migration is more effectively inhibited and cell apoptosis is more effectively promoted.
Owner:WEIFANG MEDICAL UNIV

Monitoring and imaging method for interaction of label-free nano plastic and single cell

The invention discloses a label-free nano plastic and single cell interaction monitoring imaging method which comprises the following steps: placing a sensing chip attached to cells on an SPRM, and recording a cell SPR image in the interaction process of the cells on the sensing chip and nano plastic; after the cell SPR image and the cell bright field image are compared to determine the corresponding area of the single cell in the SPR image, the deformation data of the cell membrane in the interaction process of the single cell and the nano plastic are obtained according to the SPR signal intensity of the area of the single cell, and the monitoring of the interaction of the nano plastic and the single cell under the resolution of the single cell is realized. The technical support is provided for researching the binding kinetics and cytotoxicity of the nano plastic.
Owner:ZHEJIANG UNIV

Beta-lactoglobulin fluorescent probe as well as preparation method and application thereof

The invention discloses a beta-lactoglobulin fluorescent probe as well as a preparation method and application thereof, the structural formula of the probe is (C30H25N4I), the probe is combined with beta-lactoglobulin through non-covalent interaction, a fluorescence signal is triggered to be remarkably enhanced, and low-background fluorescence detection of the beta-lactoglobulin is realized. The probe has low cytotoxicity and excellent mitochondrial targeting ability, and provides a powerful tool for visualization of beta-lactoglobulin in living cells. After being combined with beta-lactoglobulin, a sample can generate obvious color change under the irradiation of an ultraviolet lamp, and the change can be used for evaluating the content of active beta-lactoglobulin in the sample, so that the rapid detection of the milk protein level in a beverage is realized. The beta-lactoglobulin fluorescent probe disclosed by the invention has a wide application prospect in the fields of biological imaging, milk protein detection, beverage quality control and the like.
Owner:YANGZHOU UNIV

Antibacterial coating with TaCu nano multilayer structure and preparation method thereof

The invention belongs to the technical field of biological coatings, and provides an antibacterial coating with a TaCu nano multilayer structure and a preparation method of the antibacterial coating. The antibacterial coating comprises a Cu layer and a Ta layer which are sequentially and alternately stacked on a base body, the Cu layer is in contact with the base body, and the Ta layer is the outermost layer. The Cu layers and the Ta layers are sequentially and alternately stacked on the substrate, the Cu < 2 + > layer-by-layer release delays the release rate, the cytotoxicity is reduced, and a lasting antibacterial effect is obtained; meanwhile, due to introduction of Ta, the osteogenesis performance of the matrix is effectively enhanced, and proliferation of bone cells is promoted. The antibacterial coating does not show cytotoxicity to rat bone marrow mesenchymal stem cells, can inhibit growth of staphylococcus aureus for a long time, is beneficial to promoting proliferation of osteoblasts, and can be used as an antibacterial coating for the surface of a bone implant. The preparation method of the antibacterial coating provided by the invention has the advantages of simple process, high deposition speed and high bonding strength.
Owner:SHANGHAI RUICHANG MEDICAL TECHNOLOGY CO LTD

Recombinant I-type collagen Pro.C1 as well as preparation method and application thereof

The invention discloses a recombinant I type collagen Pro.C1. The amino acid sequence of the recombinant I type collagen Pro.C1 is as shown in SEQ ID NO. 5. The invention also discloses a coding gene, an expression vector, host bacteria, a preparation method and application of the gene. The recombinant I-type collagen Pro.C1 can be expressed by prokaryote fermentation, has the advantages of no cytotoxicity, high biological activity, good water solubility and stable quality, has the effects of promoting cell proliferation, promoting collagen regeneration and tightening and supporting, and can be widely applied to the fields of skin care products, skin repair dressings, medical cosmetology and the like.
Owner:广东普言生物科技有限公司

Lipoic acid derivative-based lipid compound, composition and preparation method and application thereof

The invention provides a lipid compound based on a lipoic acid derivative, a composition as well as a preparation method and application of the lipid compound. When the lipoic acid-derived lipid provided by the invention is used as a delivery carrier of a nucleic acid drug, because disulfide bonds in the compound are split under the action of glutathione in cells, the compound is degraded, so that the timely release of nucleic acid is triggered, the cytotoxicity caused by accumulation of the compound in the cells is well reduced, and the bioavailability of the nucleic acid drug is improved. The biocompatibility is good. When the lipid nanoparticle composition is used as a carrier to deliver nucleic acid drugs, the lipid nanoparticle composition has excellent delivery efficiency and excellent spleen targeting performance, and the nucleic acid drugs can be preferentially delivered to the spleen.
Owner:TAN KAH KEE INNOVATION LAB +1

Use of novel pomalidomide derivatives in the treatment of brain diseases

The present invention relates to a novel pomalidomide derivative that exhibits improved pharmacological effects compared to pomalidomide, and is used to treat brain diseases. The novel pomalidomide derivative developed in the present invention has excellent binding ability to cereblon, is almost non-cytotoxic, has low possibility of teratogenic side effects, and can regulate TNF-α expression, as well as suppress oxidative stress and has excellent in vivo pharmacokinetic stability, and shows excellent effects of improving the decrease in motor ability, which is a symptom of Parkinson's disease, and increasing the expression of tyrosine hydroxylase, which is decreased in Parkinson's disease, and can be used for the prevention or treatment of brain diseases such as Parkinson's disease.
Owner:AEVIS BIO INC

Recombinant human serum albumin-collagen binding domain fusion protein for tumor-specific targeting matrix, and use thereof

Provided is a recombinant human serum albumin-collagen binding domain (CBD) fusion protein for tumor-specific targeting matrix and its use in specific targeted treatment of a solid tumor. HSA and the CBD generate gene fusion in the form of different molecular structures, and can be expressed in a constructed recombinant engineered host. A pharmaceutical recombinant fusion protein is obtained through large-scale fermentation. The recombinant fusion protein shows tumor-specific targeting of solid tumors and can be used as a starting material of a broad-spectrum matrix carrier. The recombinant fusion protein is coupled with any tumor treatment drug, small-molecule compound, or cytotoxic protein to form an innovative pharmaceutical composition. The pharmaceutical composition of the recombinant fusion protein is also long-acting, can prolong a half-life of the conjugate drug in vivo, and has a significantly better clinical curative efficacy on anti-tumor than that of a monomer drug.
Owner:HUATONG FORTURN (CHINA) CO LTD +2

E3 ubiquitin enzyme mutant, modification and protein targeted degradation system thereof and application of E3 ubiquitin enzyme mutant

The invention discloses an E3 ubiquitin enzyme mutant as well as modification and a protein targeted degradation system and application thereof, and particularly relates to a series of targeted protein degradation enhanced E3 ubiquitin enzymes (Trim21-N) and a modification method thereof, the E3 ubiquitin enzymes (Trim21-N) are obtained by modifying a wild type Trim21 (wtTrim21) protein structural domain, and the E3 ubiquitin enzymes comprise Trim21-a, Trim21-b, Trim21-c, Trim21-d, Trim21-e and Trim21-f. The efficiency of degrading the target protein through the ubiquitin proteasome is remarkably improved, and the method has the characteristics of strong endogenous and exogenous universality, high specificity, ubiquitin proteasome dependence, low cytotoxicity, strong cell compatibility and the like on the degradation of the target protein. The invention provides E3 ubiquitin enzyme (Trim21-N) based on a targeted protein degradation enhancement version and an exogenous fluorescence report degradation system of the E3 ubiquitin enzyme (Trim21-N), preferably Trim21-e with the optimal degradation effect, and the E3 ubiquitin enzyme (Trim21-N) is named as delta Trim21. The invention further provides an endogenous protein degradation system based on the delta Trim21. The method has the characteristics of high specificity, rapidness and small module, so that the method can be used for researching various biological and disease mechanisms, including the fields of cell targeted therapy, cell mechanism exploration, genetic engineering and the like.
Owner:EAST CHINA NORMAL UNIV

Application of polypeptide in regulation of immunocompetence of macrophages

PendingCN118987165Alow toxicityHas anti-inflammatory biological activityPeptide/protein ingredientsAntipyreticInflammatory factorsDisease
The invention provides an application of a polypeptide in regulation of immunocompetence of macrophages. The amino acid sequence of the polypeptide is shown as SEQ ID NO: 1. The polypeptide can reduce the amount of NO released by LPS-induced mouse macrophages RAW 264.7 and inhibit the amount of inflammatory factors (IL-6, IL-1beta and TNF-alpha) released by the LPS-induced macrophages, has anti-inflammatory biological activity, is low in cytotoxicity and good in safety, can be used for non-therapeutic application in immunoregulation activity of the macrophages, and has good application prospects. The compound can also be used for preparing medicines for preventing and / or treating inflammatory diseases.
Owner:JIMEI UNIV

Application of iNOS inhibitor in preparation of medicine for relieving cell injury caused by toxin combined exposure

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an iNOS inhibitor in preparation of a medicine for relieving cellular injury caused by toxin combined exposure. KK-1 cells serve as a research model, it is shown for the first time that MC-LR and NaNOS combined contamination can remarkably up-regulate the expression level of iNOS protein, and it is found through tests that Nos2 gene silencing can remarkably relieve tight junction damage and cell apoptosis caused by toxin combined exposure in the KK-1 cells; it is revealed for the first time that iNOS is a core target of toxin combined exposure induced cell tight junction damage and apoptosis, and the blank of toxic mechanism research in toxin combined exposure is filled. The application provides a new direction for a detoxification strategy of environmental toxin combined exposure, provides a theoretical basis for developing an iNOS-targeted inhibitor, and also provides a new target for etiological recognition, early diagnosis and prevention of related diseases caused by environmental toxin combined exposure.
Owner:ZHENGZHOU UNIV

Antibody variant combinations and uses thereof

Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and / or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.
Owner:GENMAB BV

Antibodies, antibody drug conjugates, preparation and uses thereof

The present disclosure provides antibodies specifically targeting CD142, antibody drug conjugates, preparation and uses thereof. An antibody, or antigen-binding fragment thereof, that binds to CD142 is covalently linked to a cytotoxic payload via a linker. Antibodies, or antigen-binding fragments thereof, and antibody drug conjugates that bind to CD142 exhibit a cytotoxic effect on tumor cells.
Owner:MULTITUDE THERAPEUTICS INC

Hydrogen bond organic framework material, preparation method and application of hydrogen bond organic framework material in dopamine detection

The invention provides a hydrogen bond organic framework material, a preparation method and application of the hydrogen bond organic framework material in dopamine detection, the preparation method of the hydrogen bond organic framework material comprises the following steps: S1, dissolving 1, 3, 5-tri (4-carboxyphenyl) benzene in an organic solvent to obtain an organic solution; and S2, dropwise adding an alcohol solvent into the organic solution to react to obtain turbid liquid, and drying to obtain the hydrogen bond organic framework material. The hydrogen bond organic framework material HOF-BTB prepared by the invention is a porous material, has two-dimensional (2D) pi-pi stacked hexagonal lamellas and complex eight interpenetration, generates a one-dimensional channel in the framework, and is simple in preparation process, mild in synthesis condition, low in cost, good in biocompatibility and low in cytotoxicity; and due to rigid organic construction molecules, the compound shows excellent fluorescence performance. The HOF-BTB material has high selectivity due to differential recognition of binding sites, and can be effectively applied to detection of dopamine.
Owner:PHOTONICS INTEGRATION (WENZHOU) INNOVATION RES INST

A complete medium for culturing DF-1 cells

The present invention discloses a complete medium for culturing DF-1 cells, including DMEM basal medium 13.7g / L, insulin, non-essential amino acids, transferrin, glutathione, ascorbyl phosphate, sodium selenite, ethanolamine, hydrocortisone, and newborn calf serum. Wherein non-essential amino acids include glycine, alanine, proline, serine, and asparagine. A complete medium for culturing DF-1 cells provided by the present invention can well promote the proliferation of DF-1 cells, can achieve the same proliferation effect as high-concentration fetal bovine serum, and is suitable for the adherent culture of DF-1 cells; using low-concentration newborn calf serum, it is possible to greatly avoid the batch differences, unstable culture results, cytotoxicity, and high risk of carrying pathogens brought by the culture medium with high-concentration serum, narrow application range, expensive fetal bovine serum, and high culture cost; the components are simple, the culture medium preparation process is short in time consumption, the culture efficiency is high, the repeatability is good, and it is suitable for batch production.
Owner:INNER MONGOLIA OPTIMUS BIOTECHNOLOGY CO LTD

Antibody targeting DLL3 and use of antibody

An antibody targeting DLL3 and a use of the antibody. The DLL3 antibody shows excellent specificity and binding capacity, a chimeric antigen receptor derived therefrom shows excellent killing capacity against tumor cells, the cytotoxicity is low, and the side effects are low.
Owner:NEUKIO BIOTHERAPEUTICS (SHANGHAI) CO LTD